In a phase 2 trial of patients with gastrointestinal cancers, avatrombopag helped 70% of those receiving chemotherapy to stay on treatment schedule, compared with 17% receiving placebo.

In a phase 2 clinical trial, Mass General Brigham Cancer Institute researchers found that the oral drug avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia ...